WeinsteinL.: Chemotherapy of Microbial Disease in The Pharmacological Basis of Therapeutics, GoodmanL. S., and GilmanA., Editors, 4th edition, The Macmillan Company, New York, New York, p. 1154, 1970.
2.
MeyersF. H., JawetzE., and GoldfienA.: Review of Medical Pharmacology, 2nd edition, Lange Medical Publications, Los Altos, California, pp. 473–474, 1970.
OsolA., PrattR., and AltschuleM. D.: The United States Dispensatory and Physicians' Pharmacology, 26th Ed., J. B. Lippincott Co., Philadelphia, pp. 128–129, 1967.
5.
Anon: Med. Letter Drug. Ther.14: 11–14 (Jan. 21) 1972.
6.
ShibataK.: Immunological Cross-sensitization of Cephalothin and Its Related Compounds With Benzylpenicillin, Nature212: 419–420 (Oct. 22) 1966.
RothschildP. D., and DotyD. B.: Cephalothin Reaction After Penicillin Sensitization, J. Amer. Med. Assoc.196: 372–373 (Apr. 25) 1966.
9.
ThoburnR.: Studies on the Epidemiology of Adverse Drug Reactions, IV. The Relationship of Cephalothin and Penicillin Allergy, J. Amer. Med. Assoc.198: 345–348 (Oct. 24) 1966.
10.
AbrahamG.: Immunologic Relationship Between Penicillin and Cephalothin in Humans, Clin. Res.16: 126 (Jan.) 1968.
11.
ScholandJ. F.: Anaphylaxis to Cephalothin in a Patient Allergic to Penicillin, J. Amer. Med. Assoc.206: 130–132 (Sept. 30) 1968.
12.
BennerE. J.: The Cephalosporin Antibiotics in Antimicrobial Therapy, KaganB. M., Editor, W. B. Saunders Co., Philadelphia, pp. 41–42, 1970.
13.
American Hospital Formulary Service, published by the American Society of Hospital Pharmacists, Washington, D.C., 1970.
14.
SenecaH.: Biological Basis of Chemotherapy of Infections and Infestations.F. A. Davis Co., Philadelphia, p. 816, 1971.
15.
SaslanS.: Cephalosporins. Med. Clinics N. Amer.54: 1217–1228 (Sept.) 1970.
16.
SheimanL.: Thrombocytopenia Caused by Cephalothin Sodium. Occurrence in a Penicillin-Sensitive Individual, J. Amer. Med. Assoc.203: 601–603 (Feb. 19) 1968.
MolthanL.: Cephalothin and Positive Direct Coombs' Tests, Transfusion6: 517 (Nov.-Dec.) 1966.
23.
GralnickH. R.: Hemolytic Anemia Associated With Cephalothin, J. Amer. Med. Assoc.217: 1193–1197 (Aug. 30) 1971.
24.
PickeringM. J.: Declining Renal Function Associated With the Administration of Cephalothin, S. Med. J.63: 426–428 (Apr.) 1970.
25.
KabinsS. A., and CohenS.: Cephalothin Serum Levels in the Azotemic Patient, Antimicrobial Agents and Chemotherapy1964, pp. 207–214, 1965.
26.
KuninC. M., and AtukN.: Excretion of Cephaloridine and Cephalothin in Patients With Renal Impairment, N. E. J. Med.274: 654–656 (Mar. 24) 1966.
27.
PerkinsR. L.: Cephalothin and Cephaloridine: Comparative Pharmacodynamics in Chronic Uremia, Amer. J. Med. Sci.257: 116–124 (Jan.) 1969.
28.
EgetmeyerA.: Cephalothin Serum Concentration and Urinary Excretion in Patients With Chronic Renal Insufficiency, Deut. Med. Wochenschr.96: 494–498 (Mar. 19) 1971.
29.
EykynS.: Use and Control of Cephalosporins, J. Clin. Path.24: 419–429 (July) 1971.
30.
YamasakuF.: A Study of the Kinetics of Cephalosporins in Renal Impairment, Postgrad. Med. J.46 (Suppl.): 57–59 (Oct.) 1970.
31.
KirbyW. M. M.: Pharmacokinetics of the Cephalosporins in Healthy Volunteers and Uremic Patients, Postgrad. Med. J.47 (Suppl.): 41–46 (Feb.) 1971.
32.
LeeC. C.: Pharmacological and Toxicological Studies on Cephalothin, Clin. Med.70: 1123–1138 (June) 1963.
33.
KuninC. M.: A Guide to Use of Antibiotics in Patients With Renal Disease, A Table of Recommended Doses and Factors Governing Serum Levels, Ann. Intern. Med.67: 151–158 (July) 1967.
34.
StraubeW., and KonigK.: Nil nocere! Zur. Frage der Nephrotoxzitat von Cephaloridin, Munch. Med. Wochenschr.111: 665–669 (Mar. 21) 1969.
35.
VerzettiG.: Sulla Nefrotossicita della Cefaloridina: Deduzioni Dall'impiego Clinico della Sostanza, Minerva. Med.61: 2779–2786 (June 23) 1970.
36.
DillonM. L., and PostlewaitR. W.: Cephaloridine in Patients With Impaired Renal Function, J. Amer. Med. Assoc.218: 250–251 (Oct. 11) 1971.
37.
AtkinsonR. M.: Acute Toxicity of Cephaloridine, an Antibiotic Derived From Cephalosporin C, Toxicol. Appl. Pharmacol.8: 398–406 (May) 1966.
38.
AtkinsonR. M.: Subacute Toxicity of Cephaloridine to Various Species, Toxicol. Appl. Pharmacol.8: 407–428 (May) 1966.
39.
WellesJ. S.: Toxicity, Distribution and Excretion of Cephaloridine in Laboratory Animals, Antimicrobial Agents and Chemotherapy1965, pp. 863–869, 1966/
40.
FlemingP. C., and JaffeD.: The Nephrotoxic Effect of Cephaloridine, Postgrad. Med. J.43 (Suppl): 89–90 (Aug.) 1967.
41.
PerkinsR. L.: Cephaloridine and Cephalothin: Comparative Studies of Potential Nephrotoxicity, J. Lab. Clin. Med.71: 75–84 (Jan.) 1968.
42.
ApicellaM. A.: Cephaloridine Treatment of Bacterial Infections, Amer. J. Med. Sci.251: 266–276 (Mar.) 1966.
43.
GonellaJ. S.: Cephaloridine Treatment of Bacterial Infections, Antimicrobial Agents and Chemotherapy1965, pp. 901–907, 1966.
44.
HollowayW. J., and ScottE. G.: Clinical Experience With Cephaloridine, Antimicrobial Agents and Chemotherapy 1965, pp. 916–921, 1966.
45.
HermansP. E.: Laboratory and Clinical Evaluation of Cephaloridine, a Cephalosporin Derivative, Antimicrobial Agents and Chemotherapy 1965, pp. 879–887, 1966.
HinmanA. R., and WolinskyE.: Nephrotoxicity Associated With the Use of Cephaloridine, J. Amer. Med. Assoc.200: 724–726 (May 22) 1967.
50.
FoordR. D.: A Multi-Centre Dose-Response Trial With Cephaloridine, Postgrad. Med. J.43 (Suppl.): 63–69 (Aug.) 1967.
51.
GalbraithH. J. B.: A Clinical Study of Cephaloridine, Brit. J. Clin. Pract.21: 331–336 (July) 1967.
52.
ThorntonG. F., and AndrioleV. T.: Laboratory and Clinical Studies of a New Antibiotic, Cephaloridine, in the Treatment of Gram-Positive Infections, Yale J. Biol. Med.39: 9–20 (Aug.) 1966.
53.
KaplanK.: Cephaloridine. Studies of Therapeutic Activity and Untoward Effects, Arch. Int. Med.121: 17–23 (Jan.) 1968.
54.
VerneyR. E.: Acute Infections Seen in General Practice and Treated Wtih Cephaloridine, Postgrad. Med. J.43 (Suppl.): 166–169 (Aug.) 1967.
55.
TempestB., and AustrianR.: Cephaloridine and Penicillin G in the Treatment of Pneumococcal Pneumonia, Ann. Int. Med.66: 1109–1115 (June) 1967.
56.
BennerE. J.: Laboratory and Clinical Comparison of Cephaloridine and Cephalothin, Antimicrobial Agents and Chemotherapy 1965, pp. 883–893, 1966.
57.
LaneR. A.: Cephaloridine, Laboratory and Clinical Evaluation, Antimicrobial Agents and Chemotherapy 1966, pp. 88–95, 1967.
58.
DennisM.: Clinical Evaluation of Cephaloridine, Antimicrobial Agents and Chemotherapy 1965, pp. 724–727, 1966.
59.
SenecaH.: Treatment of Urinary Tract Infections With Cephaloridine. J. Urol.97: 153–155 (Jan.) 1967.
60.
FluxM.: Evaluation of Cephaloridine in Infants and Children. Antimicrobial Agents and Chemotherapy 1965, pp. 933–936, 1966.
61.
CohenP. G.: Laboratory and Clinical Evaluation of Cephaloridine in 78 Patients, Antimicrobial Agents and Chemotherapy 1965, pp. 894–900, 1966.
62.
DiakosG. K.:: Clinical Laboratory Experience With Cephaloridine, Antimicrobial Agents and Chemotherapy 1965, pp. 908–915. 1966.
63.
FoordR. D.: Cephaloridine and the Kidney. Progress in Antimicrobial and Anticancer Chemotherapy, Proceedings of the Sixth International Congress of Chemotherapy1: 597–604, 1970.
64.
PinesA., and RaafatH.: Controlled Comparisons of Cephaloridine With Penicillin and Streptomycin in Chronic Purulent Bronchitis, Postgrad. Med. J.43 (Suppl.): 61–63 (Aug.) 1967.
65.
BallingallD. L. K., and TurpicA. G. G.: Cephaloridine Toxicity, Lancet2: 835–836 (Oct. 14) 1967.
66.
JungersP.: Les Accidents Renaux de la Cephaloridine. A Propos de Trois Observations d'Insufficisance Renal Aigue Anurique. Presse Med.77: 1515–1518 (Oct. 18) 1969.
67.
PinesA., and RaafatH.: Cephaloridine Toxicity, Lancet2: 1309 (Dec. 16) 1967.
68.
GalbraithH. J. B.: Cephaloridine in the Hospital Management of Bacterial Infections, S. Afr. Med. J.42: 832–836 (Aug. 17) 1968.
69.
GabrielR.: Reversible Encephalopathy and Acute Renal Failure After Cephaloridine, Brit. Med. J.4: 283–284 (Oct. 31) 1970.
70.
SimpsonI. J.: Nephrotoxicity and Acute Renal Failure Associated With Cephalothin and Cephaloridine, N. Z. Med. J.74: 312–315 (Nov.) 1971.
71.
BennerE. J.: Renal Damage Associated With Prolonged Administration of Ampicillin. Cephaloridine and Cephalothin, Antimicrobial Agents and Chemotherapy 1969, pp. 417–420, 1970.
72.
FairW. R.: The Effect of Cephaloridine on Normal Renal Function, J. Urol.107: 2–3 (Jan.) 1972.
73.
MuggletonP. W.: Laboratory Evaluation of a New Antibiotic—Cephaloridine (Ceporin), Brit. Med. J.2: 1234–1237 (Nov. 14) 1964.
74.
DoddsM. G., and FoordR. D.: Enhancement by Potent Diuretics of Renal Tubular Necrosis Induced by Cephaloridine. Brit. J. Pharmacol.40: 227–236 (Oct.) 1970.
75.
IsbisterJ. P.: Penicillin Allergy. A Review of the Immunological and Clinical Aspects, Med. J. Aust.1: 1067–1074 (May 15) 1971.
76.
BaldwinD. S.: Renal Failure and Interstitial Nephritis Due to Penicillin and Methicillin, N. E. J. Med.279: 1245–1252 (Dec. 15) 1968.
77.
CurtisJ. R., and MarshallM. J.: Cephaloridine Serum Levels in Patients on Maintenance Hemodialysis, Brit. Med. J.2: 149–151 (Apr. 18) 1970.
78.
Loridine: Lilly Product Information.Eli Lilly and Company, Indianapolis, Indiana, p. 128 (April) 1972.
79.
KuninC. M., and FinkelbergZ.: Oral Cephalexin and Ampicillin: Antimicrobial Activity, Recovery in Urine, and Persistence in Blood of Uremic Patients, Ann. Intern. Med.72: 349–356 (March) 1970.
80.
BraunP.: Cephalexin and Cephaloglycin Activity In Vitro and Absorption and Urinary Excretion of Single Oral Doses in Normal Young Adults, Applied Microbiol.16: 1684–1694 (Nov.) 1968.
81.
ReisbergB. E., and MandelbaumJ. M.: Cephalexin: Absorption and Excretion as Related to Renal Function and Hemodialysis, Infect. Immunity3: 540–543 (April) 1971.
82.
PerkinsR. L.: Cephalexin: In Vitro Bacterial Susceptibility, Absorption in Volunteers, and Antibacterial Activity of Sera and Urine, Amer. J. Med. Sci.256: 122–129 (August) 1968.
83.
KabinsS. A.: Cephalexin Therapy as Related to Renal Function, Amer. J. Med. Sci.259: 133–142 (Feb.) 1970.
84.
GriffithR. S., and BlackH. R.: Cephalexin: A New Antibiotic, Clin. Med.75: 14–22 (Nov.) 1968.
85.
HenningC.: Studies of Absorption, Excretion, Antibacterial and Clinical Effect of Cephalexin, Scand. J. Infect. Dis.2: 131–138 (Nov. 2) 1970.
86.
BrogardJ. M.: Klinische Pharmakologie der Cephalexins. Studium uber Seine Verteilung im Organismus und Einfluss der Niereninsuffizienz, Int. J. Clin. Pharmacol.2 (Suppl.): 60–70 (Nov.) 1969.
87.
RegamyC.: Cephalexin und Niereninsuffizienz. Vorlaufiger Bericht, Int. J. Clin. Pharmacol.2 (Suppl.): 71–76 (Nov.) 1969.
88.
BaileyR. R.: The Effect of Impairment of Renal Function and Haemodialysis on Serum and Urine Levels of Cephalexin, Postgrad. Med. J.46 (Suppl.): 60–64 (Oct.) 1970.
89.
RegamyC., and HumairL.: Pharmacokinetics of Cephalexin in Renal Insufficiency, Postgrad. Med. J.47 (Suppl.): 69–78 (Feb.) 1971.
90.
LinquistJ. A.: Cephalexin in Patients With Renal Disease, N. E. J. Med.283: 720–723 (Oct. 1) 1970.
91.
BerganT.: Human Pharmacokinetics of Cephalexin, Pharmacology4: 264–272 (Mar. 4) 1970.
92.
de MaineJ. B., and KirbyW. M. M.: Clinical Pharmacology of Cephalexin Administered Intravenously, Antimicrobial Agents and Chemotherapy 1970, pp. 190–1941971.
93.
JohnsonW. D.: Cephaloglycin. Clinical and Laboratory Experience With an Orally Administered Cephalosporin, J. Amer. Med. Assoc.206: 2698–2702 (Dec. 16) 1968.
94.
KuninC. M., and BrandtD.: Comparative Studies of Ampicillin, Cephalothin, and a New Cephalosporin Derivative, Cephaloglycin, Amer. J. Med. Sci.255: 196–201 (March) 1968.